Merck & Co., Inc. (MRK)
Merck & Co., Inc. (MRK) Presents at 7th Annual Healthcare Symposium Transcript
Merck & Co., Inc. ( MRK ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michelle Kehily Conference Call Participants Elena Meng Michael Paas Stephen S. Morse Magdalena Sobieszczyk Presentation Unknown Attendee So our final panel of the day is about vaccines.
Here's Why Merck (MRK) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Merck & Co., Inc. ( MRK ) Shareholder/Analyst Call November 9, 2025 7:01 PM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Dean Li - Executive VP & President of Merck Research Laboratories Joerg Koglin - Senior VP & Head of General Medicine - Global Clinical Development Jannie Oosthuizen - Senior VP & President Merck U.S. Human Health Conference Call Participants Taylor Hanley - JPMorgan Chase & Co, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Nick Jennings - Goldman Sachs Group, Inc., Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Vamil Divan - Guggenheim Securities, LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3?
Merck leans on Keytruda's expanding cancer indications and new SC formulation to sustain growth momentum into 2026 after soft sales in Q3.
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Merck (MRK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Merck & Co., Inc. ( MRK ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Caroline Litchfield - Executive VP & CFO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Daina Graybosch - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Merck Q3 financial results top estimates, company lowers revenue guidance
Merck & Co Inc (NYSE:MRK, ETR:6MK) on Thursday reported third quarter 2025 earnings and revenue that surpassed Wall Street expectations, lifted by strong demand for its cancer immunotherapy Keytruda, but reduced its full-year sales outlook to reflect lower estimated tariff costs, among other factors. The pharmaceutical company's revenue for the quarter rose 4% year over year to $17.28 billion, exceeding the $16.96 billion analyst consensus estimate provided by LSEG.
Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
Merck (MRK) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $1.57 per share a year ago.
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower estimated tariff costs and other items. Sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago.
